Tenon Medical reported second quarter 2026 revenue of $1.3 million, a 127% increase year-over-year, with gross profit rising to $0.8 million and gross margin improving to 64%. The company posted a net loss of $4.1 million, or $12.35 per share. Subsequent to the quarter end, Tenon closed a public offering for $4.2 million in gross proceeds on July 1, 2026, and received FDA 510(k) clearance for its updated Catamaran SI Joint Fusion System on July 2, 2026. Additionally, the company effected a 1-for-35 reverse stock split on August 10, 2026, to regain Nasdaq compliance. Tenon Medical is a medical device company focused on treating sacro-pelvic disorders.
